サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1770170

ヒト成長ホルモン薬の世界市場

Human Growth Hormone Drugs

出版日
ページ情報
英文 335 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
ヒト成長ホルモン薬の世界市場
出版日: 2025年07月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 335 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒト成長ホルモン薬の世界市場は2030年までに52億米ドルに到達

2024年に40億米ドルと推定されるヒト成長ホルモン薬の世界市場は、2024～2030年の分析期間においてCAGR 4.2％で成長し、2030年には52億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである皮下は、CAGR 4.7%を記録し、分析期間終了時には34億米ドルに達すると予測されます。筋肉内セグメントの成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 5.8％で成長予測

米国のヒト成長ホルモン薬市場は、2024年には15億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに3億5,810万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と3.7%と予測されています。欧州では、ドイツがCAGR約3.5%で成長すると予測されています。

世界のヒト成長ホルモン薬市場- 主要動向と促進要因まとめ

ヒト成長ホルモン（HGH）医薬品は、内因性成長ホルモンの分泌不全に起因する様々な病状の治療に使用される成長ホルモンの合成製剤です。このような状態には、発育不全の原因となる小児の成長ホルモン欠乏症や、筋肉量、エネルギー、QOLの低下など様々な症状を引き起こす成人の成長ホルモン欠乏症が含まれます。HGHはまた、ターナー症候群、プラダー・ウィリー症候群、慢性腎不全の治療にも使用されます。これらの治療用途にとどまらず、HGHは筋肉量やパフォーマンスの向上にも応用されており、スポーツや加齢に関連した治療への利用が物議を醸しています。

HGH製剤の市場は、バイオテクノロジーの進歩によりその有効性と安全性が向上したため、大幅に拡大しています。組換えDNA技術の開発は、体内で生成される天然の成長ホルモンを忠実に模倣した、安全で効果的なHGHの大量生産を可能にした極めて重要な要因です。これはまた、合成品が利用できるようになる前に使用されていたヒト下垂体からの抽出物に比べ、副作用の発生を抑えることにも役立っています。さらに、使いやすい注射ペンや徐放性製剤の開発など、ドラッグデリバリーシステムの強化により、患者のコンプライアンスと治療成績が向上しています。大手術や火傷からの回復など、HGHの新たな応用の可能性が研究によって明らかにされ続けているため、その治療効果の範囲は広がり続けています。

ヒト成長ホルモン薬市場の成長は、HGH療法を必要とする疾患の有病率の増加、診断技術の進歩、様々な身体機能におけるHGHの役割のより深い理解など、いくつかの要因によって牽引されています。診断方法の改善により、小児と成人の両方で成長ホルモン欠乏症がより頻繁に特定されるようになり、これがHGH治療の需要を押し上げています。さらに、HGHの用途拡大やドラッグデリバリー方法の改善を目指した研究開発が進められていることも、市場拡大に大きく寄与しています。さらに、加齢に関連した症状の管理や全体的な健康状態の改善におけるHGH療法の利点に対する消費者の認識と受容が高まっており、これが市場の拡大をさらに刺激しています。新たな地域や新たな適応症に対する規制当局の承認もまた、この市場の持続的成長に重要な役割を果たしており、HGH療法の世界の普及と採用を促進しています。

セグメント

投与経路（皮下、筋肉内、静脈内、経口）、流通チャネル（病院薬局、専門薬局、小売薬局、オンライン薬局）、用途（成長ホルモン欠乏症、ターナー症候群、特発性低身長症（ISS）、プラダー・ウィリー症候群（PWS）、その他の用途）

調査対象企業の例

  • Eli Lilly and Company
  • EMD Serono, Inc.
  • Ambrx, Inc.
  • Ferring International Center SA
  • Hanmi Pharmaceuticals Co., Ltd.
  • Aileron Therapeutics, Inc.
  • Alteogen, Inc.
  • CinnaGen Co.
  • Genexine, Inc.
  • IPP Group Ltd.
  • BIOSIDUS SA
  • Corlison Pte. Limited
  • Access Pharmaceuticals
  • ERBAGIL srl
  • Kynerion S.r.l.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 世界市場概要
  • 主要企業
  • 市場動向と促進要因
  • パイプライン分析
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-7129

Global Human Growth Hormone Drugs Market to Reach US$5.2 Billion by 2030

The global market for Human Growth Hormone Drugs estimated at US$4.0 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Intramuscular segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 5.8% CAGR

The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$358.1 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Human Growth Hormone Drugs Market - Key Trends and Drivers Summarized

Human Growth Hormone (HGH) drugs consist of synthetic forms of growth hormones used to treat various medical conditions caused by inadequate endogenous growth hormone production. These conditions include growth hormone deficiency in children, which can lead to stunted growth, and adult growth hormone deficiency, which may cause a variety of symptoms such as decreased muscle mass, energy, and quality of life. HGH is also used in treating Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. Beyond these therapeutic uses, HGH has applications in improving muscle mass and performance, which has led to its controversial use in sports and aging-related treatments.

The market for HGH drugs has expanded significantly due to advancements in biotechnology that have improved the efficacy and safety of these drugs. The development of recombinant DNA technology has been a pivotal factor in enabling the mass production of safe and effective HGH, which closely mimics the natural growth hormone produced in the body. This has also helped reduce the occurrence of adverse reactions compared to earlier extracts from human pituitary glands, which were used before synthetic versions became available. Furthermore, enhancements in drug delivery systems, including the development of easier-to-use injectable pens and sustained-release formulations, have improved patient compliance and treatment outcomes. As research continues to unveil new potential applications of HGH, such as in recovery from major surgeries and burns, the scope of its therapeutic benefits continues to broaden.

The growth in the human growth hormone drugs market is driven by several factors, including an increase in the prevalence of conditions requiring HGH therapy, advancements in diagnostic techniques, and a better understanding of the role of HGH in various bodily functions. Improved diagnostic methods have led to more frequent identification of growth hormone deficiencies in both children and adults, which, in turn, boosts the demand for HGH treatments. Additionally, ongoing research and development efforts aimed at expanding the applications of HGH and improving drug delivery methods are significant contributors to market growth. Moreover, there is an increasing consumer awareness and acceptance of the benefits of HGH therapy in managing age-related conditions and improving overall health outcomes, which further stimulates market expansion. Regulatory approvals in new regions and for new indications also play a crucial role in the sustained growth of this market, facilitating the wider availability and adoption of HGH therapies globally.

SCOPE OF STUDY:

The report analyzes the Human Growth Hormone Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Route of Administration (Subcutaneous, Intramuscular, Intravenous, Oral); Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy, Online Pharmacy); Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS), Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 46 Featured) -

  • Eli Lilly and Company
  • EMD Serono, Inc.
  • Ambrx, Inc.
  • Ferring International Center SA
  • Hanmi Pharmaceuticals Co., Ltd.
  • Aileron Therapeutics, Inc.
  • Alteogen, Inc.
  • CinnaGen Co.
  • Genexine, Inc.
  • IPP Group Ltd.
  • BIOSIDUS SA
  • Corlison Pte. Limited
  • Access Pharmaceuticals
  • ERBAGIL srl
  • Kynerion S.r.l.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Human Growth Hormone Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to Human Growth Hormones
    • Recombinant Human Growth Hormones
    • Evolution of Recombinant Human Growth Hormones (hGH)
  • GLOBAL MARKET OVERVIEW
    • Global Human Growth Hormone Drugs Market to Witness Steady Growth
    • List of Select Approved Prescription Daily-dose hGH Products by Indication
    • List of Select Approved Prescription Weekly-dose hGH Products by Indication
    • Subcutaneous Route Dominates Human Growth Hormone Drugs Market
    • Growth Hormone Deficiency Application Leads the Human Growth Hormone Drugs Market
    • North America and Europe Dominate, Asia-Pacific to Witness Fastest Growth
    • Market Restraints
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Prevalence of Growth Hormone Deficiency Disorders
    • Pediatric GHD Rules, while Adult GHD Remains Underserved
    • Worldwide Recombinant Human Growth Hormone Market by Indication (2020): Percentage Breakdown of Value Sales for Pediatric GHD; Adult GHD, Turner Syndrome & Idiopathic Short Stature; and Others
    • Long-Acting hGH Drugs - A Game Changer for the Human Growth Hormone Drugs Market
    • Approval of Novo Nordisk's Once-Weekly Sogroya to Transform the Market Landscape
    • Other Noteworthy Developments in the Long Acting hGH Space
    • Patent Expiry Paves Way for the Emergence of Biosimilars
    • Strong Innovation Drive Takes Hold of the hGH Industry
    • Manufacturers Bet on Novel Drug Delivery Technologies
    • Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard
    • Needle-less Drug Delivery Systems to Wipe Out of Syringes
    • Drug Delivery Device Options for Marketed hGH Products
    • Major Growth Restraining Factors
    • Complex Delivery System
    • High Cost of hGH Treatment
    • Biosimilars Threaten Revenue Growth Erosion
  • PIPELINE ANALYSIS
    • Select Daily and Long-Acting Human Growth Hormone Products List in Phase III Pipeline
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Specialty Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Turner Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Idiopathic Short Stature (ISS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Prader-Willi Syndrome (PWS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 42: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 43: World Human Growth Hormone Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 164: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Latin America Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 167: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Latin America Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 170: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Latin America Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 182: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Africa Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Africa 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 185: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Africa Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Africa 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 188: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Africa Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Africa 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION